FFOX - ETF AI Analysis
Top Page
FundX Future Fund Opportunities ETF (FFOX)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Results
The fund has delivered positive year-to-date performance, showing it has benefited from recent market trends.
Several Strong Top Holdings
Key positions like Guardant Health, Mercury Systems, FirstCash, Onto Innovation, and Carpenter Technology have shown strong gains, helping support the ETF’s overall returns.
Broad Sector Diversification
Holdings spread across technology, industrials, health care, consumer sectors, and more help reduce the impact if any one industry struggles.
Negative Factors
High Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of your returns go toward fees each year.
Recent Short-Term Weakness
The ETF has slipped over the past one and three months, suggesting some recent pressure on its holdings.
Heavy U.S. Focus
With the vast majority of assets in U.S. companies, the fund offers limited diversification across global markets.
FFOX vs. SPDR S&P 500 ETF (SPY)
AUM220.23M
RegionNorth America
Expense Ratio1.02%
Beta0.99
IssuerFundX
Inception DateJun 10, 2025
Dividend Yield1.74%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume16,000
30 Day Avg. Volume23,374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
35.86Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering74
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FFOX Summary
FundX Future Fund Opportunities ETF (FFOX) is an actively managed fund that looks for “future-focused” themes instead of tracking a set index. It mainly invests in smaller U.S. companies tied to big long-term trends like new technology, health care innovation, and industrial growth. Examples of holdings include Guardant Health and Halozyme, both involved in advanced medical treatments. Someone might invest in FFOX for growth potential and diversification across several forward-looking sectors. However, because it focuses on smaller companies and specific themes, its price can be more volatile and can go up and down more than the overall market.
How much will it cost me?The FundX Future Fund Opportunities ETF (FFOX) has an expense ratio of 1.00%, meaning you’ll pay $10 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on identifying and investing in sectors aligned with transformative global trends.
What would affect this ETF?FFOX's focus on transformative megatrends like technology and healthcare positions it to benefit from advancements in innovation and demographic shifts, which could drive long-term growth. However, its exposure to small- and mid-cap companies may make it more sensitive to economic downturns or interest rate hikes, which can negatively impact these sectors. Additionally, regulatory changes in healthcare or technology could pose risks to its top holdings.
FFOX Top 10 Holdings
FFOX is leaning into U.S.-focused future themes, with a noticeable tilt toward health care innovators and industrial names. On the upside, Millicom and BWX Technologies are doing much of the heavy lifting, while FirstCash has quietly become a steady engine for the fund. Globus Medical is also helping, though its momentum looks a bit stretched. On the flip side, Guardant Health and Ionis Pharmaceuticals are losing steam, acting as small brakes on performance. Overall, the ETF is concentrated in niche U.S. growth stories rather than broad Big Tech giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Guardant Health | 3.34% | $7.36M | $17.20B | 206.74% | 61 Neutral | |
| ― | 3.12% | $6.88M | ― | ― | ― | |
| Halozyme | 2.91% | $6.40M | $7.89B | 22.46% | 73 Outperform | |
| Mercury Systems | 2.14% | $4.72M | $6.71B | 120.97% | 57 Neutral | |
| Ionis Pharmaceuticals | 2.13% | $4.68M | $12.64B | 120.99% | 61 Neutral | |
| Globus Medical | 2.02% | $4.45M | $11.11B | 35.31% | 82 Outperform | |
| FirstCash | 1.97% | $4.33M | $9.64B | 66.90% | 74 Outperform | |
| Everpure | 1.87% | $4.13M | $26.41B | 57.64% | 64 Neutral | |
| Onto Innovation | 1.86% | $4.09M | $12.85B | 175.67% | 82 Outperform | |
| Carpenter Technology | 1.83% | $4.04M | $23.30B | 102.95% | 75 Outperform |
FFOX Technical Analysis
Positive
―
Price Trends
27.90
Positive
28.10
Positive
27.87
Positive
Market Momentum
0.04
Negative
55.02
Neutral
91.02
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFOX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 27.99, equal to the 50-day MA of 27.90, and equal to the 200-day MA of 27.87, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 55.02 is Neutral, neither overbought nor oversold. The STOCH value of 91.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FFOX.
FFOX Peer Comparison
Comparison Results
Performance Comparison
FFOX
FundX Future Fund Opportunities ETF
28.34
3.15
12.50%
FEPI
REX FANG & Innovation Equity Premium Income ETF
―
―
―
AIPI
REX AI Equity Premium Income ETF
―
―
―
DUNK
Dana Unconstrained Equity ETF
―
―
―
LFGY
YieldMax Crypto Industry & Tech Portfolio Option Income ETF
―
―
―
GPTY
YieldMax AI & Tech Portfolio Option Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents